This is a transformative label expansion for AUVELITY into a large, underserved market with no FDA-approved competition for Alzheimer's agitation. Watch for the company's commercial launch execution and prescription trends over the next 2-4 quarters. The conference call on May 1 may provide revenue guidance or launch expectations.
Price Chart
Executive Summary
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment for a condition affecting up to 76% of Alzheimer's patients. This is a major label expansion for an already-approved drug (MDD), supported by Breakthrough Therapy designation and Priority Review, with a patent estate extending to at least 2043.
Key Facts
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026.
- AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors for this indication.
- The sNDA was granted Breakthrough Therapy designation and evaluated under Priority Review.
- Approval supported by Phase 3 ADVANCE-1 and ACCORD-2 trials showing statistically significant improvement on primary and key secondary endpoints.
- AUVELITY is already FDA-approved for major depressive disorder (approved 2022) and has been administered to over 300,000 patients.
- Patent estate extends to at least 2043.
- Alzheimer's disease affects more than 7 million Americans; agitation reported in up to 76% of patients.
Financial Impact
No specific financial figures provided in the filing. The approval opens a large addressable market (up to ~5.3M Alzheimer's patients with agitation) for an existing commercial product.
Risk Factors
- Commercial adoption may be slower than expected due to the elderly patient population and caregiver-driven prescribing dynamics.
- Payer coverage and reimbursement for the new indication are not yet established.
- AUVELITY carries a boxed warning for suicidal thoughts and behaviors, which may limit use in some patients.
- Competition from off-label antipsychotics and other emerging therapies could limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-197857 |
| Document: axsm-20260430.htm | 0001193125-26-197857 |
| Document: 0001193125-26-197857-index-headers.html | 0001193125-26-197857 |
| Document: 0001193125-26-197857-index.html | 0001193125-26-197857 |
| Document: 0001193125-26-197857.txt | 0001193125-26-197857 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access